Tildrakizumab Antibody

SKU: orb1980659

Description

Tildrakizumab is a humanized monoclonal antibody targeting the IL-23 p19 subunit with high affinity (Kd 136 pM). It is a research tool for investigating the pathogenesis of psoriasis and has been utilized in both in vitro binding assays and in vivo preclinical models of autoimmune inflammation.

Research Area

Immunology & Inflammation

Images & Validation

−

Key Properties

−

CAS Number	1326244-10-3
MW	144.44 kDa
Purity	> 95%
Target	IL Receptor,Interleukin

Bioactivity

−

Target IC50	HeLa cells:23 pM
In Vivo	Tildrakizumab (100 mg/kg, subcutaneous injection, every two weeks, up to 9 months) demonstrates good tolerability in cynomolgus monkeys (toxicity study). Read more...
In Vitro	Tildrakizumab inhibits IL-23-induced STAT3 signaling in HeLa cells expressing human IL-23Rα and IL-12Rβ1 receptors, with an IC50 of 23 pM, and reduces the affinity of IL-23 for IL-23Rα through negative allosteric modulation. Read more...

Storage & Handling

−

Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

MK 3222, MK3222, MK-3222, ILReceptor, IL Receptor, IL-23, SCH 900222, SCH900222, SCH-900222, Tildrakizumab

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Quick Database Links

Gene Symbol

IL Receptor,Interleukin

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols